iSAM Funds UK Ltd Makes New $441,000 Investment in Agilent Technologies, Inc. (NYSE:A)

iSAM Funds UK Ltd bought a new position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 3,286 shares of the medical research company's stock, valued at approximately $441,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. CKW Financial Group boosted its holdings in shares of Agilent Technologies by 114.9% in the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company's stock valued at $25,000 after buying an additional 100 shares in the last quarter. Global X Japan Co. Ltd. boosted its holdings in shares of Agilent Technologies by 161.1% in the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company's stock valued at $25,000 after buying an additional 116 shares in the last quarter. Redwood Park Advisors LLC bought a new stake in shares of Agilent Technologies in the 4th quarter valued at about $27,000. Lee Danner & Bass Inc. bought a new stake in shares of Agilent Technologies in the 4th quarter valued at about $29,000. Finally, Hanson & Doremus Investment Management boosted its holdings in shares of Agilent Technologies by 66.5% in the 4th quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company's stock valued at $35,000 after buying an additional 105 shares in the last quarter.

Insider Transactions at Agilent Technologies

In other news, Director Daniel K. Podolsky sold 1,819 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $116.46, for a total transaction of $211,840.74. Following the sale, the director now owns 35,737 shares of the company's stock, valued at $4,161,931.02. This trade represents a 4.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Rodney Gonsalves sold 1,908 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the sale, the vice president now directly owns 21,786 shares in the company, valued at $2,657,456.28. The trade was a 8.05% decrease in their position. The disclosure for this sale can be found here.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on A shares. Wells Fargo & Company lowered their price target on shares of Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Jefferies Financial Group decreased their price objective on shares of Agilent Technologies from $135.00 to $116.00 and set a "hold" rating for the company in a research report on Monday, April 21st. Robert W. Baird decreased their price objective on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Barclays decreased their price objective on shares of Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Finally, TD Cowen increased their price objective on shares of Agilent Technologies to $135.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $143.00.

Agilent Technologies Stock Performance

A opened at $113.48 on Wednesday. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $154.65. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $32.35 billion, a PE ratio of 26.09, a P/E/G ratio of 3.20 and a beta of 1.27. The firm has a 50 day moving average of $110.23 and a two-hundred day moving average of $127.89.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. The company had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. On average, analysts anticipate that Agilent Technologies, Inc. will post 5.54 EPS for the current year.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.